Excerpt of story provided by Crain's Cleveland Business
Written by Chuck Soder
Venture developer JumpStart Inc. has committed to invest $250,000 in a Garfield Heights company that aims to commercialize a drug to treat patients with atrial fibrillation, a condition characterized by an irregular heartbeat.
ChanRx, which two years ago spun out from drug development services provider ChanTest Corp., also of Garfield Heights, will use the money to complete development of an intravenous version of its drug, called Vanoxerine. ChanRx expects the intravenous version to work faster than an oral version of the drug, which is being tested on humans...
Read the complete article.
*To view articles two weeks old or less, you must have a print or digital subscription. Articles older than two weeks are free.*
JumpStart cannot be responsible for broken links on third party sites.